Yale School of Medicine
New Haven, Connecticut, 06510, United States
NCT Number: NCT04605081
This study will test the effectiveness of naltrexone/bupropion medication as a maintenance therapy for the treatment of loss-of-control eating and weight loss following bariatric surgery. This is a controlled test of whether, amongst responders to acute treatments, naltrexone/bupropion medication results in superior maintenance and longer-term outcomes compared with placebo.
This study is active but is not currently recruiting participants.
Notify Me18 year–70 year
All sexes
Interventional
Phase 2 / Phase 3
New Haven, Connecticut, 06510, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
NB medication will be taken daily in pill form.
Other names: Contrave
Placebo will be inactive and taken daily in pill form.
Time frame: From baseline interview at study enrollment to after the 12-week treatment
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 loss-of-control eating per month.
Time frame: From post-treatment to the 6-month follow-up
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 loss-of-control eating per month.
Time frame: From post-treatment to the 12-month follow-up
Relapse will be scored as a yes/no (categorical variable); this categorical variable will be based on frequency of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Relapse category will be defined as ≥4 loss-of-control eating per month.
Time frame: From baseline at study enrollment to after the 12-week treatment
BMI is calculated using measured height and weight
Time frame: From post-treatment to the 6-month follow-up
BMI is calculated using measured height and weight
Time frame: From post-treatment to the 12-month follow-up
BMI is calculated using measured height and weight
Time frame: From baseline interview at study enrollment to after the 12-week treatment
Loss-of-control eating frequency is a continuous variable of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Loss-of-control eating frequency will be based on the past 28 days and defined as loss-of-control eating episodes per month.
Time frame: From post-treatment to the 6-month follow-up
Loss-of-control eating frequency is a continuous variable of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Loss-of-control eating frequency will be based on the past 28 days and defined as loss-of-control eating episodes per month.
Time frame: From post-treatment to the 12-month follow-up
Loss-of-control eating frequency is a continuous variable of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Loss-of-control eating frequency will be based on the past 28 days and defined as loss-of-control eating episodes per month.
Time frame: From baseline interview at study enrollment to after the 12-week treatment
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Time frame: From post-treatment to the 6-month follow-up
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Time frame: From post-treatment to the 12-month follow-up
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Time frame: From baseline at study enrollment to after the 12-week treatment
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Patient Health Questionnaire - 9. Scores range from 0-27 (0=no depressive symptoms, 27=greater depressive symptoms).
Time frame: From post-treatment to the 6-month follow-up
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Patient Health Questionnaire - 9. Scores range from 0-27 (0=no depressive symptoms, 27=greater depressive symptoms).
Time frame: From post-treatment to the 12-month follow-up
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Patient Health Questionnaire - 9. Scores range from 0-27 (0=no depressive symptoms, 27=greater depressive symptoms).
Yale University
Other
Pharmacological and Behavioral Treatments to Treat Loss-of-Control Eating and Improve Weight Outcomes After Bariatric Surgery: Maintenance Treatment (Stage 2a)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04599478
Body Weight, Loss-of-Control Eating
New Haven, Connecticut, United States
View Trial DetailsNCT04599504
Body Weight, Loss-of-Control Eating
New Haven, Connecticut, United States
View Trial DetailsNCT07017179
Body Weight, Nutrition Disorders
Jinan, China
View Trial DetailsNCT06728124
Body Weight, Nutrition Disorders
Beijing, China
View Trial Details